Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

@article{Houghton2014InitialT,
  title={Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program},
  author={P. Houghton and R. Kurmasheva and E. Kolb and J. Wu and R. Gorlick and J. Maris and M. Smith},
  journal={Pediatric Blood & Cancer},
  year={2014},
  volume={61}
}
  • P. Houghton, R. Kurmasheva, +4 authors M. Smith
  • Published 2014
  • Medicine
  • Pediatric Blood & Cancer
  • TAK‐701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c‐Met transduced signaling and c‐Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK‐701 based on immunochemical detection of HGF/c‐Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK‐701 was tested using a dose of 30 mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK‐701 did not… CONTINUE READING
    5 Citations

    Topics from this paper

    References

    SHOWING 1-10 OF 19 REFERENCES
    Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors
    • 24
    • PDF
    Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program
    • 7
    Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas
    • 70
    • PDF
    The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas
    • 41
    The pediatric preclinical testing program: Description of models and early testing results
    • 385